Lisa Ludwig

8 papers receiving 77 citations

Hit Papers

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agoni...2025202620255101520

Peers

Lisa Ludwig
Comparison fields: 5 of 30
  • Endocrinology, Diabetes and Metabolism 36
  • Pulmonary and Respiratory Medicine 23
  • Molecular Biology 19
  • Oncology 19
  • Cardiology and Cardiovascular Medicine 12
Replace Song Han with:
Song Han South Korea
Takuya Haraguchi Japan
RJ Hinchliffe United Kingdom
Charles J. Blijdorp Netherlands
S Butterworth United Kingdom
H. B. Bueno-de-Mesquita Netherlands
Katherine Young United Kingdom
Yanping Qiu China
Monika Tomaszewska‐Kiecana Poland
Shuhei Sekiguchi Japan
Lisa Ludwig relative to Song Han South Korea Song Han's profile →
Citations per field
00.5×1.5×2.3×
Song Han · 1×
Citations per year

Countries citing papers authored by Lisa Ludwig

Since Specialization
Citations

This map shows the geographic impact of Lisa Ludwig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Ludwig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Ludwig more than expected).

Fields of papers citing papers by Lisa Ludwig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Ludwig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Ludwig. The network helps show where Lisa Ludwig may publish in the future.

Co-authorship network of co-authors of Lisa Ludwig

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Ludwig. A scholar is included among the top collaborators of Lisa Ludwig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Ludwig. Lisa Ludwig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
#WorkIndexed citations
1 0
2
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetesbreakdown →
21
3 12
4 4
5 17
6 16
7 3
8 5
9
[Effect of aureomycin].
1

About Lisa Ludwig

Lisa Ludwig is a scholar working on Applied Microbiology and Biotechnology, Geriatrics and Gerontology and Cancer Research, having authored 9 papers that have together received 79 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (2 papers), Diabetes Treatment and Management (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (36 citations), Applied Microbiology and Biotechnology (2 citations) and Family Practice (2 citations). Lisa Ludwig has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Bruno Guerci, Patrice Darmon, Thomas Rémen, Laura Fernández Landó, Luis Nevárez Ruiz, Yanyun Chen, David A. Cox, Wen‐Shuo Wu, Rong Liu and Stanley H. Hsia. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Archives of Disease in Childhood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026